Market Cap 1.50B
Revenue (ttm) 207.54M
Net Income (ttm) -187.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -90.16%
Debt to Equity Ratio 0.00
Volume 1,401,500
Avg Vol 1,374,826
Day's Range N/A - N/A
Shares Out 73.38M
Stochastic %K 4%
Beta 1.63
Analysts Strong Sell
Price Target $31.33

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through...

Industry: Health Information Services
Sector: Healthcare
Phone: 212 295 5800
Address:
1540 Broadway, 24th Floor, New York, United States
Jasooon
Jasooon Jun. 23 at 2:47 AM
$SDGR chatGPT is correct or nah?
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:47 AM
$SDGR 🚀 1. AI-Driven Review for Faster Drug Approvals • Makary is actively deploying AI tools (e.g., Elsa and a “cderGPT” initiative) across FDA centers to streamline and accelerate scientific review processes . • His goal: compress drug-approval timelines from ~10 months to as little as 1–2 months for “national priority” therapies , and even push for “instant” reviews in certain cases . Bull case link: An accelerated, AI-enabled FDA process favors companies like Schrödinger that generate AI/physics-powered data packages. Their computational platform can provide high-quality early evidence—positioning them as ideal beneficiaries of speedier review pathways.
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:46 AM
$SDGR 🏷 2. “National Priority Vouchers” for Strategic Innovation • Makary’s “Commissioner’s National Priority Review Voucher” program will fast-track approvals for firms aligned with key public health goals—potentially including rare diseases, antibiotics, or affordability-driven innovation . • The targeted guidance encourages early data submission and real‑time FDA interaction . Bull case link: Schrödinger’s emerging clinical assets (like SGR-1505, -2921, -3515) could qualify for these vouchers. If they align with national priorities (e.g. rare disorders or oncology), they may gain an expedited approval path, boosting valuation and limiting development downside.
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:45 AM
$SDGR 🧪 3. Replacing Animal Testing with AI & Human‑Relevant Models • Makary’s FDA is phasing out animal testing requirements (especially for mAbs) in favor of AI-based modeling and organ-on-a-chip methods . • This reflects a preference for computational chemistry and in-silico safety validation . Bull case link: Deeply in Schrödinger’s wheelhouse—their physics-based modeling platform can meet or exceed the FDA’s AI-driven, non-animal standards. That strengthens their role as a core R&D partner in later-stage validation and preclinical safety screening.
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 22 at 8:08 PM
$SDGR the question looks like, how far do we overshoot the gap. I bet not too far
0 · Reply
scott52
scott52 Jun. 20 at 5:47 PM
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 20 at 4:47 PM
$SDGR a dollar away from a legendary gap fill. So close
0 · Reply
StockHunter75
StockHunter75 Jun. 20 at 3:03 PM
$SDGR Dhorts getting greedy so we buy more. They will eventually cover or get burned.
0 · Reply
scott52
scott52 Jun. 18 at 4:16 PM
$SDGR Shareholders meeting today where Ramy and the board get to pretend like everything is going great. IPO in 2020. Came public at a $2.8B valuation. Today? $1.5B valuation. And shareholders have been massively diluted along the way. Meanwhile $100 invested in the SP in early 2020 would be worth $200 or so now. Some unfortunate changes in environment. Higher rates. The rise of Chinese bios and AI. More platforms doing what they do. But also just horrible management. So much promise. And very few tangible results. Maybe the next five years are better. But there's no reason to think so. Show me!
2 · Reply
shrwd
shrwd Jun. 17 at 11:49 PM
$SDGR According to my calculations, were heading back to 17$ area. Double bottom?
1 · Reply
Latest News on SDGR
Schrödinger Announces CFO Appointment

May 20, 2025, 6:30 AM EDT - 4 weeks ago

Schrödinger Announces CFO Appointment


Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

May 7, 2025, 5:59 PM EDT - 6 weeks ago

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript


Schrödinger: Still Waiting On A Catalyst

Mar 2, 2025, 1:24 AM EST - 4 months ago

Schrödinger: Still Waiting On A Catalyst


Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:27 PM EST - 4 months ago

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript


Schrödinger to Participate in Upcoming Investor Conferences

Feb 24, 2025, 8:30 AM EST - 4 months ago

Schrödinger to Participate in Upcoming Investor Conferences


Schrödinger (SDGR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:51 AM EST - 7 months ago

Schrödinger (SDGR) Q3 2024 Earnings Call Transcript


Schrödinger Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 6:50 AM EST - 7 months ago

Schrödinger Reports Third Quarter 2024 Financial Results


Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 12:46 AM EDT - 11 months ago

Schrödinger, Inc. (SDGR) Q2 2024 Earnings Call Transcript


Jasooon
Jasooon Jun. 23 at 2:47 AM
$SDGR chatGPT is correct or nah?
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:47 AM
$SDGR 🚀 1. AI-Driven Review for Faster Drug Approvals • Makary is actively deploying AI tools (e.g., Elsa and a “cderGPT” initiative) across FDA centers to streamline and accelerate scientific review processes . • His goal: compress drug-approval timelines from ~10 months to as little as 1–2 months for “national priority” therapies , and even push for “instant” reviews in certain cases . Bull case link: An accelerated, AI-enabled FDA process favors companies like Schrödinger that generate AI/physics-powered data packages. Their computational platform can provide high-quality early evidence—positioning them as ideal beneficiaries of speedier review pathways.
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:46 AM
$SDGR 🏷 2. “National Priority Vouchers” for Strategic Innovation • Makary’s “Commissioner’s National Priority Review Voucher” program will fast-track approvals for firms aligned with key public health goals—potentially including rare diseases, antibiotics, or affordability-driven innovation . • The targeted guidance encourages early data submission and real‑time FDA interaction . Bull case link: Schrödinger’s emerging clinical assets (like SGR-1505, -2921, -3515) could qualify for these vouchers. If they align with national priorities (e.g. rare disorders or oncology), they may gain an expedited approval path, boosting valuation and limiting development downside.
0 · Reply
Jasooon
Jasooon Jun. 23 at 2:45 AM
$SDGR 🧪 3. Replacing Animal Testing with AI & Human‑Relevant Models • Makary’s FDA is phasing out animal testing requirements (especially for mAbs) in favor of AI-based modeling and organ-on-a-chip methods . • This reflects a preference for computational chemistry and in-silico safety validation . Bull case link: Deeply in Schrödinger’s wheelhouse—their physics-based modeling platform can meet or exceed the FDA’s AI-driven, non-animal standards. That strengthens their role as a core R&D partner in later-stage validation and preclinical safety screening.
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 22 at 8:08 PM
$SDGR the question looks like, how far do we overshoot the gap. I bet not too far
0 · Reply
scott52
scott52 Jun. 20 at 5:47 PM
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 20 at 4:47 PM
$SDGR a dollar away from a legendary gap fill. So close
0 · Reply
StockHunter75
StockHunter75 Jun. 20 at 3:03 PM
$SDGR Dhorts getting greedy so we buy more. They will eventually cover or get burned.
0 · Reply
scott52
scott52 Jun. 18 at 4:16 PM
$SDGR Shareholders meeting today where Ramy and the board get to pretend like everything is going great. IPO in 2020. Came public at a $2.8B valuation. Today? $1.5B valuation. And shareholders have been massively diluted along the way. Meanwhile $100 invested in the SP in early 2020 would be worth $200 or so now. Some unfortunate changes in environment. Higher rates. The rise of Chinese bios and AI. More platforms doing what they do. But also just horrible management. So much promise. And very few tangible results. Maybe the next five years are better. But there's no reason to think so. Show me!
2 · Reply
shrwd
shrwd Jun. 17 at 11:49 PM
$SDGR According to my calculations, were heading back to 17$ area. Double bottom?
1 · Reply
Estimize
Estimize Jun. 17 at 3:01 PM
Wall St is expecting -0.83 EPS for $SDGR Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/sdgr?chart=historical&metric_name=eps&utm_c
0 · Reply
StockHunter75
StockHunter75 Jun. 17 at 11:11 AM
$SDGR it's bottomed out its a good time to start a position.
1 · Reply
StockHunter75
StockHunter75 Jun. 16 at 6:01 PM
$SDGR Buying some
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 16 at 5:31 PM
$SDGR I grabbed some shares at 20.99. Little impatient but will add more if we go under 20
0 · Reply
luckydirb
luckydirb Jun. 15 at 10:23 PM
$SDGR would be only worse in the long term if the current CEO didn't step down for a much stronger leadership. The current CEO has no vision no wisdom running this company. When the stock price declined all the way from $110, he did absolutely nothing to stop that. It took him 10 years to realize AI is actually a good label for the company. He hired the worst CFO ever. All the major strategical actions since the IPO only hurted his company.
1 · Reply
JimmyBluechips
JimmyBluechips Jun. 14 at 9:04 PM
$SDGR the old yeezer scientists have a hard time learning how to use this, the new ones coming out of school etc do not. Sdgr’s timeline is over many years from now. If you don’t have the time, get it for youngins in your family, they’ll thank you later. Imo
2 · Reply
scott52
scott52 Jun. 13 at 8:03 PM
$SDGR Down more than TEVA. And TEVA is in Israel. LoL.
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 13 at 6:19 PM
$SDGR for LT holders it’s best we fill the 19.30 gap imo, so close
1 · Reply
Chomo
Chomo Jun. 13 at 6:01 PM
$SLP $SDGR $PPTA $HYMC yesterday fall was not enough?
0 · Reply
JimmyBluechips
JimmyBluechips Jun. 13 at 4:57 PM
$SDGR 21.50 sure is tempting. If I wasn’t already well positioned I’d accumulate here, but it’s worth it to wait for lower for me personally.
0 · Reply
scott52
scott52 Jun. 13 at 3:03 PM
$SDGR So, let me get this straight. SLP, with a valuation 1/4 of SDGRs and revenue that isn't even 1/2 of SDGRs, trimmed it's yearly revenue guidance by $10M and THAT is somehow the cause of a $450M drawdown in the valuation of SDGR? Are market participants mentally retarded? Or is this just total corruption?
1 · Reply
Buckanator
Buckanator Jun. 13 at 2:32 PM
$SDGR I’ve been waiting for $21/share and I got it. The gap down today though is a bit alarming but this sell off is overdone
0 · Reply